Diagnostic test company PanBio posted a first half sales jump of 49% to stay on track for a full year revenue target of $16.9 million.
National accounting firm Deloittes has launched its Technology Fast 50 program for 2002.
BresaGen has reassured investors its projects are not threatened by potential regulation of stem cell research in Australia.
A million-dollar collaboration between nano-drug company Starpharma and diagnostics specialist PanBio Ltd has come unstuck.
Cryosite, a Sydney-based biotechnology service company that stores frozen biological material, is going public.
Biota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million.
A new network for the medical device industry is gearing up for launch.
Plant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government.
South Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest.
Drug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.
Australian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago.
Agriculture Victoria's 40-year bantamised hen project has entered the commercialisation phase, beginning a joint research deal with an elite international breeder.
A screening instrument that enables drug company technicians to run parallel tests has been released by Melbourne-based company Axon Instruments (ASX: AXN).
Brisbane biotech business Xenome Ltd is moving closer to human trials with a pain-killing molecule derived from the venom of a marine shellfish.
Australia's first artificial hearts are to be implanted in human patients within weeks, according to the developer.